Skip to main content

Table 2 Median total doses for dose escalation of PET-positive local recurrence and pelvic lymph nodes and median total dose for oligometastatic bone lesions

From: A survey among German-speaking radiation oncologists on PET-based radiotherapy of prostate cancer

  Median total dose in EQD2(1.5 Gy) [Gy] Median single dose [Gy] RT technique
PET-positive local recurrence 70.00 (range: 56.89–85.71) 2.00 (range: 1.80–4.30) SQB: 24.4% (21/86)
    SIB: 66.3% (57/86)
    No boost: 2.3% (2/86)
    Other: 7.0% (6/86), one with LDR-brachytherapy with 108 Gy
PET-positive pelvic LNs 62.00 (range: 52.61–80.00) 2.00 (range: 1.80–2.60) SQB: 19.8% (13/84)
    SIB: 75.6% (65/84)
    No boost: 3.5% (3/86)
    Other: 1.2% (1/86) with a SBRT boost
Oligometastatic bone lesions 64.64 (range: 31.43–197.14) 5.00 (range: 1.80–20.00) CRT: 51.4% (56/109)
    SBRT: 43.1% (47/109)
    No RT: 5.5% (6/109)
  1. RT radiotherapy, LN lymph nodes, EQD2(1.5 Gy) equivalent dose at fractionation of 2 Gy with α/β = 1.5 Gy, SQB sequential boost, SIB simultaneous integrated boost, LDR low dose rate, SBRT stereotactic body radiotherapy, CRT conventional fractionated radiotherapy